Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BRAF = v-raf murine sarcoma viral oncogene homolog B1 FLUS = follicular lesion of undetermined significance FNAB = fine-needle aspiration biopsy FTC = follicular thyroid carcinoma HRAS = homologous to the oncogene from the Harvey rat sarcoma virus KRAS = homologous to the oncogene from the Kirsten rat sarcoma virus NRAS = first isolated from a human neuroblastoma/neuroblastoma RAS = viral oncogene homolog PAX8 = paired box 8 PCR = polymerase chain reaction PPAR-gamma = peroxisome proliferator-activated receptor gamma PTC = papillary thyroid carcinoma RAS = rat sarcoma RET = rearranged during transfection tyrosine-kinase proto-oncogene SM = somatic mutation SNP = single-nucleotide polymorphism.
|
27214302 |
2016 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Mutational dynamics between primary and relapse neuroblastomas.
|
26121086 |
2015 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here we describe a miRNA, miR-380-5p, that represses p53 expression via a conserved sequence in the p53 3' untranslated region (UTR). miR-380-5p is highly expressed in mouse embryonic stem cells and neuroblastomas, and high expression correlates with poor outcome in neuroblastomas with neuroblastoma derived v-myc myelocytomatosis viral-related oncogene (MYCN) amplification. miR-380 overexpression cooperates with activated HRAS oncoprotein to transform primary cells, block oncogene-induced senescence and form tumors in mice.
|
20871609 |
2010 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Additionally, Ras family members (Hras1, Kras2 and Nras) and the downstream effectors Pik3ca and Braf, were sequenced from twenty-five neuroblastomas arising in neuroblastoma-prone transgenic mice.
|
16822308 |
2006 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice.
|
15814359 |
2005 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the amount of p21ras-GTP bound was higher in pPNET than in neuroblastoma cells.
|
9619634 |
1998 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Favorable outcomes of patients with advanced NB were distinguished by high Ha-ras and high trk A expression, and unfavorable outcomes were distinguished by low Ha-ras and low trk A expression.
|
9781958 |
1998 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the correlation between telomerase activity and other biological characteristics reported as prognostic markers (MYCN gene amplification, loss of heterogeneity (LOH) in the short arm of chromosome 1, trk-A expression, Ha-ras p21 expression, and DNA ploidy), we investigated these biological features in 105 untreated neuroblastomas.
|
9516827 |
1997 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that, in neuroblastoma, activation of p21ras is not associated with RA-induced differentiation.
|
7576949 |
1995 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
N-myc amplification was found in neuroblastomas with low expression of trk A and of Ha-ras genes.
|
8625212 |
1995 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening.
|
8625168 |
1995 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification.
|
7982238 |
1994 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings suggest that c-src and c-Ha-ras play important roles in the neural differentiation of infantile neuroblastomas.
|
2039993 |
1991 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of Ha-ras p21 was thought to be a clinically important marker for prognosis in children with neuroblastoma.
|
1873783 |
1991 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings from unmanipulated human neuroblastomas indicate that the Ha-ras gene product (p21) might play a role in the mechanism(s) controlling aggressiveness in this type of tumor in vivo and that the Ha-ras p21 detected by a simple and reproducible immunohistochemical procedure may be of clinical importance in predicting prognosis in patients with this malignancy.
|
3276397 |
1988 |
Neuroblastoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|